Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer's disease

Valerie T.Y. Tan, Bruce G. Mockett, Shane M. Ohline, Karen D. Parfitt, Hollie E. Wicky, Katie Peppercorn, Lucia Schoderboeck, Mohamad Fairuz Yahaya, Warren P. Tate, Stephanie M. Hughes, Wickliffe C. Abraham

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease driven in large part by accumulated deposits in the brain of the amyloid precursor protein (APP) cleavage product amyloid-β peptide (Aβ). However, AD is also characterised by reductions in secreted amyloid precursor protein-alpha (sAPPα), an alternative cleavage product of APP. In contrast to the neurotoxicity of accumulated Αβ, sAPPα has many neuroprotective and neurotrophic properties. Increasing sAPPα levels has the potential to serve as a therapeutic treatment that mitigates the effects of Aβ and rescue cognitive function. Here we tested the hypothesis that lentivirus-mediated expression of a human sAPPα construct in a mouse model of AD (APPswe/PS1dE9), begun before the onset of plaque pathology, could prevent later behavioural and electrophysiological deficits. Male mice were given bilateral intra-hippocampal injections at 4 months of age and tested 8-10 months later. Transgenic mice expressing sAPPα performed significantly better than untreated littermates in all aspects of the spatial water maze task. Expression of sAPPα also resulted in partial rescue of long-term potentiation (LTP), tested in vitro. These improvements occurred in the absence of changes in amyloid pathology. Supporting these findings on LTP, lentiviral-mediated expression of sAPPα for 3 months from 10 months of age, or acute sAPPα treatment in hippocampal slices from 18 to 20 months old transgenic mice, completely reversed the deficits in LTP. Together these findings suggest that sAPPα has wide potential to act as either a preventative or restorative therapeutic treatment in AD by mitigating the effects of Aβ toxicity and enhancing cognitive reserve.

Original languageEnglish
Article number7
JournalMolecular Brain
Volume11
Issue number1
DOIs
Publication statusPublished - 9 Feb 2018
Externally publishedYes

Fingerprint

Lentivirus
Amyloid beta-Protein Precursor
Memory Disorders
Alzheimer Disease
Long-Term Potentiation
Amyloid
Transgenic Mice
Cognitive Reserve
human alpha-sAPP protein
Pathology
Therapeutics
Neurodegenerative Diseases
Cognition

Keywords

  • Amyloid
  • Amyloid precursor protein
  • APP/PS1 mouse
  • Hippocampus
  • Lentivirus
  • Long-term potentiation
  • Memory

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer's disease. / Tan, Valerie T.Y.; Mockett, Bruce G.; Ohline, Shane M.; Parfitt, Karen D.; Wicky, Hollie E.; Peppercorn, Katie; Schoderboeck, Lucia; Yahaya, Mohamad Fairuz; Tate, Warren P.; Hughes, Stephanie M.; Abraham, Wickliffe C.

In: Molecular Brain, Vol. 11, No. 1, 7, 09.02.2018.

Research output: Contribution to journalArticle

Tan, Valerie T.Y. ; Mockett, Bruce G. ; Ohline, Shane M. ; Parfitt, Karen D. ; Wicky, Hollie E. ; Peppercorn, Katie ; Schoderboeck, Lucia ; Yahaya, Mohamad Fairuz ; Tate, Warren P. ; Hughes, Stephanie M. ; Abraham, Wickliffe C. / Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer's disease. In: Molecular Brain. 2018 ; Vol. 11, No. 1.
@article{1291c48c249f4a568487f53d48c4bd84,
title = "Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a neurodegenerative disease driven in large part by accumulated deposits in the brain of the amyloid precursor protein (APP) cleavage product amyloid-β peptide (Aβ). However, AD is also characterised by reductions in secreted amyloid precursor protein-alpha (sAPPα), an alternative cleavage product of APP. In contrast to the neurotoxicity of accumulated Αβ, sAPPα has many neuroprotective and neurotrophic properties. Increasing sAPPα levels has the potential to serve as a therapeutic treatment that mitigates the effects of Aβ and rescue cognitive function. Here we tested the hypothesis that lentivirus-mediated expression of a human sAPPα construct in a mouse model of AD (APPswe/PS1dE9), begun before the onset of plaque pathology, could prevent later behavioural and electrophysiological deficits. Male mice were given bilateral intra-hippocampal injections at 4 months of age and tested 8-10 months later. Transgenic mice expressing sAPPα performed significantly better than untreated littermates in all aspects of the spatial water maze task. Expression of sAPPα also resulted in partial rescue of long-term potentiation (LTP), tested in vitro. These improvements occurred in the absence of changes in amyloid pathology. Supporting these findings on LTP, lentiviral-mediated expression of sAPPα for 3 months from 10 months of age, or acute sAPPα treatment in hippocampal slices from 18 to 20 months old transgenic mice, completely reversed the deficits in LTP. Together these findings suggest that sAPPα has wide potential to act as either a preventative or restorative therapeutic treatment in AD by mitigating the effects of Aβ toxicity and enhancing cognitive reserve.",
keywords = "Amyloid, Amyloid precursor protein, APP/PS1 mouse, Hippocampus, Lentivirus, Long-term potentiation, Memory",
author = "Tan, {Valerie T.Y.} and Mockett, {Bruce G.} and Ohline, {Shane M.} and Parfitt, {Karen D.} and Wicky, {Hollie E.} and Katie Peppercorn and Lucia Schoderboeck and Yahaya, {Mohamad Fairuz} and Tate, {Warren P.} and Hughes, {Stephanie M.} and Abraham, {Wickliffe C.}",
year = "2018",
month = "2",
day = "9",
doi = "10.1186/s13041-018-0348-9",
language = "English",
volume = "11",
journal = "Molecular Brain",
issn = "1756-6606",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer's disease

AU - Tan, Valerie T.Y.

AU - Mockett, Bruce G.

AU - Ohline, Shane M.

AU - Parfitt, Karen D.

AU - Wicky, Hollie E.

AU - Peppercorn, Katie

AU - Schoderboeck, Lucia

AU - Yahaya, Mohamad Fairuz

AU - Tate, Warren P.

AU - Hughes, Stephanie M.

AU - Abraham, Wickliffe C.

PY - 2018/2/9

Y1 - 2018/2/9

N2 - Alzheimer's disease (AD) is a neurodegenerative disease driven in large part by accumulated deposits in the brain of the amyloid precursor protein (APP) cleavage product amyloid-β peptide (Aβ). However, AD is also characterised by reductions in secreted amyloid precursor protein-alpha (sAPPα), an alternative cleavage product of APP. In contrast to the neurotoxicity of accumulated Αβ, sAPPα has many neuroprotective and neurotrophic properties. Increasing sAPPα levels has the potential to serve as a therapeutic treatment that mitigates the effects of Aβ and rescue cognitive function. Here we tested the hypothesis that lentivirus-mediated expression of a human sAPPα construct in a mouse model of AD (APPswe/PS1dE9), begun before the onset of plaque pathology, could prevent later behavioural and electrophysiological deficits. Male mice were given bilateral intra-hippocampal injections at 4 months of age and tested 8-10 months later. Transgenic mice expressing sAPPα performed significantly better than untreated littermates in all aspects of the spatial water maze task. Expression of sAPPα also resulted in partial rescue of long-term potentiation (LTP), tested in vitro. These improvements occurred in the absence of changes in amyloid pathology. Supporting these findings on LTP, lentiviral-mediated expression of sAPPα for 3 months from 10 months of age, or acute sAPPα treatment in hippocampal slices from 18 to 20 months old transgenic mice, completely reversed the deficits in LTP. Together these findings suggest that sAPPα has wide potential to act as either a preventative or restorative therapeutic treatment in AD by mitigating the effects of Aβ toxicity and enhancing cognitive reserve.

AB - Alzheimer's disease (AD) is a neurodegenerative disease driven in large part by accumulated deposits in the brain of the amyloid precursor protein (APP) cleavage product amyloid-β peptide (Aβ). However, AD is also characterised by reductions in secreted amyloid precursor protein-alpha (sAPPα), an alternative cleavage product of APP. In contrast to the neurotoxicity of accumulated Αβ, sAPPα has many neuroprotective and neurotrophic properties. Increasing sAPPα levels has the potential to serve as a therapeutic treatment that mitigates the effects of Aβ and rescue cognitive function. Here we tested the hypothesis that lentivirus-mediated expression of a human sAPPα construct in a mouse model of AD (APPswe/PS1dE9), begun before the onset of plaque pathology, could prevent later behavioural and electrophysiological deficits. Male mice were given bilateral intra-hippocampal injections at 4 months of age and tested 8-10 months later. Transgenic mice expressing sAPPα performed significantly better than untreated littermates in all aspects of the spatial water maze task. Expression of sAPPα also resulted in partial rescue of long-term potentiation (LTP), tested in vitro. These improvements occurred in the absence of changes in amyloid pathology. Supporting these findings on LTP, lentiviral-mediated expression of sAPPα for 3 months from 10 months of age, or acute sAPPα treatment in hippocampal slices from 18 to 20 months old transgenic mice, completely reversed the deficits in LTP. Together these findings suggest that sAPPα has wide potential to act as either a preventative or restorative therapeutic treatment in AD by mitigating the effects of Aβ toxicity and enhancing cognitive reserve.

KW - Amyloid

KW - Amyloid precursor protein

KW - APP/PS1 mouse

KW - Hippocampus

KW - Lentivirus

KW - Long-term potentiation

KW - Memory

UR - http://www.scopus.com/inward/record.url?scp=85041834581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041834581&partnerID=8YFLogxK

U2 - 10.1186/s13041-018-0348-9

DO - 10.1186/s13041-018-0348-9

M3 - Article

C2 - 29426354

AN - SCOPUS:85041834581

VL - 11

JO - Molecular Brain

JF - Molecular Brain

SN - 1756-6606

IS - 1

M1 - 7

ER -